Edward Smith
Petoskey, MINPI 1174542781
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.7% of the total across 47 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 11.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $536 and has fallen 57.3% since, to $229 in 2022.
Across 47 payments — averaging $20.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$113
- AstraZeneca$98
- GSK$86
- Seagen Inc.$86
- Incyte Corporation$64
- Taiho Oncology, Inc.$62
- plus $451 from 16 others
What the payments were for
- Food & beverage$92897%
- Education$323%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 3 | $113 |
| AstraZeneca(2 entities) | 6 | $98 |
| GSK | 1 | $86 |
| Seagen Inc. | 5 | $86 |
| Incyte Corporation | 1 | $64 |
| Taiho Oncology, Inc. | 3 | $62 |
| Amgen | 3 | $56 |
| Bristol Myers Squibb | 2 | $48 |
| Merck | 3 | $47 |
| EMD Serono, Inc. | 3 | $44 |
| Genentech USA, Inc. | 3 | $44 |
| Lilly USA, LLC | 2 | $32 |
| Daiichi Sankyo Inc. | 2 | $31 |
| Gilead | 2 | $25 |
| Novartis | 1 | $21 |
| AMAG Pharmaceuticals, Inc. | 1 | $20 |
| Bayer | 1 | $17 |
| Johnson & Johnson | 1 | $15 |
| Rigel Pharmaceuticals, Inc. | 1 | $14 |
| Pfizer | 1 | $14 |
| CSL Behring | 1 | $11 |
| Agios Pharmaceuticals, Inc. | 1 | $11 |
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.